Comparison between conventional dosing versus personalized pharmacokinetic dosing of vancomycin: a pilot study from a Malaysian private hospital
Article Sidebar
-
Vancomycin, Conventional Dose, Personalized Dose, Pharmacokinetic
Abstract
Pharmacist led vancomycin dosing is not a common practice in private hospital settings of the Malaysian healthcare system. The lack of this pharmacist led system has led to conventional vancomycin dosing without considering the differences in patients pharmacokinetic parameters. This study aims to compare the differences in vancomycin doses between conventional dosing and pharmacist-led personalized pharmacokinetic dosing. A retrospective pilot study was conducted on inpatient adults who were prescribed with intravenous vancomycin in a private hospital. Personalized vancomycin doses were retrospectively calculated by using the pharmacokinetic parameters and was then compared with the actual conventional doses used in the patients. The area under concentration curve over 24 hours/minimum inhibitory concentration (AUC24/MIC) ratio achieved by the doses was also compared. The targeted AUC24/MIC ratio was 400-600 to ensure efficacy and safety of the therapy. A total of 24 patients with a median age of 55.50 years were conveniently sampled. The patients were mostly male (58.3%) and were admitted to the neurosurgical ward (33.3%). Vancomycin was mainly prescribed as empirical treatment (58.3%) for a median treatment period of 5.00 days (IQR 4.00 – 7.00 days). The conventional doses had significant (p < 0.001) lower median total daily dose (2000 mg versus 2500 mg) and lower AUC24/MIC ratio (385 versus 495) as compared to personalized doses. In conclusion, the personalized pharmacokinetic dosing method was significantly more able to achieve the targeted AUC24/MIC ratio. Vancomycin personalized dosing should be considered in the Malaysian private hospital setting.
Full text article
References
Ahmad, N., et al. 2009. Characteristics of community and hospital acquired meticillin resistant Staphylococcus aureus strains carrying SCCmec type IV isolated in Malaysia. Journal of Medical Microbiology, 58(9):1213–1218.
Ahmad, N., et al. 2010. Increased vancomycin minimum inhibitory concentration among Staphylococcus aureus isolates in Malaysia. Journal of Medical Microbiology, 59(12):1530–1532.
Álvarez, R., et al. 2016. Optimizing the Clinical Use of Vancomycin. Antimicrobial Agents and Chemotherapy, 60(5):2601–2609.
Appelbaum, P. C. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents, 30(5):398–408.
Bamgbola, O. 2016. Review of vancomycin-induced renal toxicity: an update. Therapeutic Advances in Endocrinology and Metabolism, 7(3):136–147.
Bauer, L. A. 2008. Applied Clinical Pharmacokinetics, 2nd edition. McGraw-Hill Publishing Company.
Begg, E. J., et al. 1989. Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations [see comments]. British Journal of Clinical Pharmacology, 28(2):137–141.
Cano, E. L., Haque, N. Z., Welch, V. L. 2012. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: a retrospective analysis of the IMPACT-HAP Database. Clinical Therapeutics, 34(1):149–157.
Cockcroft, D. W., Gault, H. 1976. Prediction of Creatinine Clearance from Serum Creatinine. Nephron, 16(1):31–41.
Contreiras, C., Legal, M., Lau, T. T. Y., Thalakada, R., Shalansky, S., Ensom, M. H. H. 2014. Identification of Risk Factors for Nephrotoxicity in Patients Receiving Extended-Duration, High-Trough Vancomycin Therapy. The Canadian Journal of Hospital Pharmacy, 67(2):126–132.
Darko, W., et al. 2003. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy, 23(5):643–650.
del Mar Fernández de Gatta Garcia, M., et al. 2007. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Medicine, 33(2):279–285.
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., Wong-Beringer, A. 2006. High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections. Archives of Internal Medicine, 166(19):2138–2144.
Liu, C., et al. 2011. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical Infectious Diseases, 52(3):285– 292.
Lodise, T. P., et al. 2009. Relationship between Initial vancomycin concentration time profile and nephrotoxicity among hospitalized patients. Clinical Infectious Diseases, 49(4):507–514.
Lodise, T. P., Lomaestro, B., Graves, J., Drusano, G. L. 2008. Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity. Antimicrobial Agents and Chemotherapy, 52(4):1330–1336.
Malaysian Society of Intensive Care 2017. Guide to antimicrobial therapy in the adult ICU 2017. ISBN: 978-967-11415-3-3.
Matzke, G. R., et al. 1984. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy, 25(4):433–437.
Matzke, G. R., et al. 1986. Clinical pharmacokinetics of vancomycin. Clinical Pharmacokinetics, 11(4):257–282.
Men, P., et al. 2016. Association between the AUC024/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis. Plos one, 11(1):e0146224.
Miller, C. L., et al. 2018. Use of individual pharmacokinetics to improve time to therapeutic vancomycin trough in pediatric oncology patients. Journal of Pediatric Pharmacology and Therapeutics, 23(2):92–99.
Ministry of Health Malaysia 2004. Clinical practice guidelines on the management of obesity. Petaling Jaya: Ministry of Health, Malaysia.
Moise-Broder, P. A., et al. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clinical Pharmacokinetics, 43(13):925–942.
Momattin, H., et al. 2016. Safety and outcome of pharmacy led vancomycin dosing and monitoring. Chemotherapy, 61(1):3–7.
Mustafa, S., et al. 2018. Determination of vancomycin pharmacokinetics in critically ill intensive care unit patients in Malaysia: A population pharmacokinetic analysis with a nonparametric approach. National Journal of Physiology, Pharmacy and Pharmacology, 8(12):1672–1679.
Neely, M. N., et al. 2014. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrobial Agents and Chemotherapy, 58(1):309–316.
Petejova, N., et al. 2012. Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 156(4):342– 347.
Pfizer 2018. Product monograph including patient medication information: Vancomycin hydrochloride for injection, Kirkland: Canada, Pfizer Canada Inc.
Pharmacy Practice & Development Division 2019. Clinical Pharmacokinetics Pharmacy Handbook 2nd edition, Petaling Jaya: Pharmacy Practice & Development Division, Ministry of Health Malaysia.
Pharmacy Services UK Health Care 2017. Clinical pharmacokinetics service & anticoagulation guidelines. 37th edition. Lexington: UK Health-Care.
Rahman, A. F. A., et al. 2013. A survey of therapeutic drug monitoring services in Malaysia. Saudi Pharmaceutical Journal, 21(1):19–24.
Rohani, M. Y., et al. 2000. Susceptibility pattern of Staphylococcus aureus isolated in Malaysian hospitals. International Journal of Antimicrobial Agents, 13(3):209–213.
Rybak, M., et al. 2009. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 66:82–98.
Rybak, M. J., Albrecht, L. M., Boike, S. C., Chandrasekar, P. H. 1990. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. Journal of Antimicrobial Chemotherapy, 25(4):679– 687.
Rybak, M. J., et al. 2020. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 77(11):835–864.
Winter, M. 2010. Basic Clinical Pharmacokinetics. page 560. 5th edition, Lippincott Williams and Wilkins. ISBN: 9780781779036.
Winter, M. A., Guhr, K. N., Berg, G. M. 2012. Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft-Gault Equation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 32(7):604–612.
Wong-Beringer, A., Joo, J., Tse, E., Beringer, P. 2011. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. International Journal of Antimicrobial Agents, 37(2):95– 101.
Ye, Z.-K., et al. 2013. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta analysis. PLoS one, 8(10):e77169.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.